Sildenafil in Acute Pulmonary Embolism
Last updated on July 2021Recruitment
- Recruitment Status
- Completed
Summary
- Conditions
- Pulmonary Embolism
- Type
- Interventional
- Phase
- Early Phase 1
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Masking Description: Treatment was blinded by the institutional pharmacy embedding the placebo or treatment pill in a gelatinous capPrimary Purpose: Basic Science
Participation Requirements
- Age
- Between 80 years and 80 years
- Gender
- Both males and females
Description
Patients with PE randomized to a single oral dose of sildenafil 50mg (n=10) or placebo (n=10) as add-on to conventional therapy. Right ventricular function evaluated immediately before and shortly after (0.5-1.5h) randomization by right heart catheterization (RHC), trans-thoracic echocardiography (T...
Patients with PE randomized to a single oral dose of sildenafil 50mg (n=10) or placebo (n=10) as add-on to conventional therapy. Right ventricular function evaluated immediately before and shortly after (0.5-1.5h) randomization by right heart catheterization (RHC), trans-thoracic echocardiography (TTE), and cardiac magnetic resonance (CMR). The primary efficacy endpoint was cardiac index measured by CMR.
Tracking Information
- NCT #
- NCT04283240
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Asger Andersen, MD,PhD Aarhus University Hospital
Get Well Soon